Azitra, Inc. (NYSEAMERICAN:AZTR) Short Interest Down 51.3% in May

Azitra, Inc. (NYSEAMERICAN:AZTR) was the recipient of a large decrease in short interest in May. As of May 29th, there was short interest totaling 61,636 shares, a decrease of 51.3% from the May 14th total of 126,538 shares. Approximately 0.4% of the shares of the stock are sold short. Based on an average daily trading volume, of 629,575 shares, the days-to-cover ratio is presently 0.1 days.

Azitra Trading Down 4.2%

AZTR opened at $0.21 on Friday. The stock has a 50-day moving average of $0.22 and a 200 day moving average of $0.25. Azitra has a 12 month low of $0.10 and a 12 month high of $2.40.

Azitra (NYSEAMERICAN:AZTR) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.24). On average, analysts expect that Azitra will post -0.25 earnings per share for the current year.

Azitra Company Profile

Azitra Inc is a clinical-stage biopharmaceutical company focused on developing live bacterial therapies for dermatological conditions. Headquartered in Cambridge, Massachusetts, the company leverages its proprietary ActoBiotic platform to formulate topical treatments that aim to modulate the skin’s native microbial ecosystem.

The company’s lead investigational therapies are being evaluated in early-phase clinical studies for inflammatory skin disorders, including atopic dermatitis and other conditions characterized by microbial imbalance.